Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191906
Status:
COMPLETED
Last Update Posted:
2010-05-25
First Post:
2005-09-12
Brief Title:
Comparison of Atomoxetine and Placebo in Children With Attention-DeficitHyperactivity Disorder ADHD andor Reading Disorder RD
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Double-Blind Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-DeficitHyperactivity Disorder Reading Disorder or Comorbid Attention-DeficitHyperactivity Disorder and Reading Disorder
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention DeficitHyperactivity Disorder ADHD patients with only Reading Disorder and patients with combined type ADHD and Reading Disorder
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B4Z-MC-LYCK | OTHER | Eli Lilly and Company | None |